Neutrophilic eccrine hidradenitis
|Neutrophilic eccrine hidradenitis|
|Classification and external resources|
Neutrophilic eccrine hidradenitis (NEH) usually is a cutaneous complication of chemotherapy, but it can also occur for other reasons. It consists of fever and non specific skin lesions. It is rare, and self-limited.
The overwhelming majority of neutrophilic eccrine hidradenitis (NEH) is seen in patients with cancer, especially leukaemia, who receive chemotherapy with a cytotoxic drug. These include: Bleomycin, chlorambucil, cyclophosphamide, cytarabine, doxorubicin, lomustine, mitoxantrone, topotecan, and vincristine.
Cancer itself, infections, and other medicinal drugs also can lead to NEH. NEH has been reported in patients with cancer who have not received any form of chemotherapy (i.e., as a paraneoplastic syndrome), in patients with HIV and/or AIDS, and after the use of paracetamol (acetaminophen). Also the use of targeted agents can lead to NEH, e.g. imatinib, a tyrosine kinase inhibitor.
The exact cause of NEH is unknown. In patients receiving chemotherapy, it has been postulated that a high concentration of the cytotoxic drug in sweat has a direct toxic effect on the eccrine glands.
Fever and a non specific skin eruption – with reddening (erythema) and swelling (oedema) of the skin – are the commonest symptoms of NEH. Patients usually present with the skin eruption 1-2 weeks after use of the cytotoxic drug. Sometimes, the skin eruption can be painful. Skin eruptions can be located on the extremities, trunk, and face. Severe lesions are rare, and can mimic cellulitis. Generalised lesions resembling erythema multiforme have been reported.
In all cases of suspected NEH, a skin biopsy should be performed, because the clinical symptoms are non specific, but the histopathological findings on the biopsy are specific. The biopsy shows characteristic changes of the eccrine glands, the major sweat glands of the body.
In NEH, eccrine gland necrosis, and neutrophils surroundings the eccrine glands, are typical findings on biopsy. If the chemotherapy has recently been administered, chemotherapy induced neutropenia may be present, and, as a result, the neutrophils may be absent. But the other characteristic finding, i.e. eccrine gland necrosis, can still be seen. A vacuolar interface dermatitis also is visible in glands and ducts, along with necrosis of the lining cells.
In addition, in patients receiving chemotherapy, keratinocyte atypia can be seen.
NEH is self-limited and usually resolves without treatment. In the overwhelming majority of the cases, spontaneous resolution occurs within 1–2 weeks.
However, if the patient developed NEH after chemotherapy, the offending cytotoxic drug has to be discontinued, and the patient must avoid this particular cytotoxic drug in the future, because NEH usually re occurs upon re exposure to the same cytotoxic drug.
Despite the fact that NEH is self limited and usually resolves without treatment, some researchers use treatment, mainly systemic corticosteroids, although the efficacy of such a therapy has not been demonstrated in a large randomised controlled clinical trial until now.
- James, William; Berger, Timothy; Elston, Dirk (2005). Andrews' Diseases of the Skin: Clinical Dermatology. (10th ed.). Saunders. ISBN 0-7216-2921-0. :780
- Neutrophilic eccrine hidradenitis. Bachmeyer C, Aractingi S. Clin Dermatol. 2000 May-Jun;18(3):319-30.
- Mucocutaneous reactions to chemotherapy. Susser WS, Whitaker-Worth DL, Grant-Kels JM. J Am Acad Dermatol. 1999;40(3):367-98.
- Neutrophilic eccrine hidradenitis. A distinctive type of neutrophilic dermatosis associated with myelogenous leukemia and chemotherapy. Harrist TJ, Fine JD, Berman RS, Murphy GF, Mihm MC Jr. Arch Dermatol. 1982;118(4):263-6.
- Unusual manifestations of acute leukemia. Case 2. Leukemia and rash: paraneoplastic or drug-induced? Blank C, Wagner HM, Hohenleutner U, Andreesen R. J Clin Oncol. 2000 Oct 1;18(19):3437-9.
- Neutrophilic eccrine hidradenitis: a case report and review of the literature. Bailey DL, Barron D, Lucky AW. Pediatr Dermatol. 1989;6(1):33-8.
- Neutrophilic eccrine hidradenitis: a case report and review of the literature. Margolis DJ, Gross PR. Cutis. 1991;48(3):198-200.
- Imatinib mesylate and dermatology part 2: a review of the cutaneous side effects of imatinib mesylate. Scheinfeld N. J Drugs Dermatol. 2006 Mar;5(3):228-31.
- Generalized idiopathic neutrophilic eccrine hidradenitis in childhood. Lee WJ, Kim CH, Chang SE, Lee MW, Choi JH, Moon KC, Koh JK. Int J Dermatol. 2010 Jan;49(1):75-8.
- Idiopathic palmoplantar eccrine hidradenitis in children. Ben-Amitai D, Hodak E, Landau M, Metzker A, Feinmesser M, David M. Eur J Pediatr. 2001 Mar;160(3):189-91.
- Neutrophilic eccrine hidradenitis: a distinctive rash associated with cytarabine therapy and acute leukemia. Flynn TC, Harrist TJ, Murphy GF, Loss RW, Moschella SL. J Am Acad Dermatol. 1984;11(4 Pt 1):584-90.
- Neutrophilic eccrine hidradenitis. Thorisdottir K, Tomecki KJ, Bergfeld WF, Andresen SW. J Am Acad Dermatol. 1993 May;28(5 Pt 1):775-7.
- Neutrophilic hidradenitis induced by chemotherapy involves eccrine and apocrine glands. Brehler R, Reimann S, Bonsmann G, Metze D. Am J Dermatopathol. 1997;19(1):73-8.
- Smoller BR, Horn TD. Chemotherapy-induced drug eruptions. In: Dermatopathology in systemic disease. Smoller BR, Horn TD (Eds). Oxford University Press. 2001.
- Recurrent neutrophilic eccrine hidradenitis. Bernstein EF, Spielvogel RL, Topolsky DL. Br J Dermatol. 1992;127(5):529-33.
- Neutrophilic eccrine hidradenitis associated with Hodgkin’s disease and chemotherapy. A case report. Beutner KR, Packman CH, Markowitch W. Arch Dermatol. 1986;122(7):809-11.
- Dapsone in prevention of recurrent neutrophilic eccrine hidradenitis. Shear NH, Knowles SR, Shapiro L, Poldre P. J Am Acad Dermatol. 1996;35(5 Pt 2):819-22.